natgillin/translations-raw huggingface dataset:
► Every time you use a new Insulatard Penfill (before you put the cartridge into the insulin delivery system). 
Svaki puta kada koristite novi Insulatard Penfill (prije nego što uložak stavite u pomagalo za primjenu inzulina):
In case of hypoglycaemia or if hypoglycaemia is suspected, Insulatard must not be injected. 
U slučaju hipoglikemije ili sumnje na hipoglikemiju Insulatard se ne smije injicirati.
Insulatard is often given in combination with fast-acting insulin preparations. 
Insulatard se često daje u kombinaciji s brzodjelujućim inzulinskim pripravcima.
Insulatard is human insulin with a gradual onset and long duration of action. 
Insulatard je humani inzulin s postupnim početkom i dugim trajanjem djelovanja.
Insulatard may be used alone or mixed with fast-acting insulin. 
Insulatard se može primjenjivati sam ili pomiješan s inzulinom brzog djelovanja.
Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between Insulatard and other insulin products. 
Bolesnicima se mora objasniti da prije svakog injiciranja uvijek provjere naljepnicu na inzulinu kako bi izbjegli slučajne zamjene lijeka Insulatard i drugih inzulinskih pripravaka.
What you need to know before you use Insulatard Do not use Insulatard 
Što morate znati prije nego počnete primjenjivati Insulatard Nemojte primjenjivati Insulatard
Insulatard is administered subcutaneously by injection in the thigh, the abdominal wall, the gluteal region or the deltoid region. 
Insulatard se primjenjuje supkutanom injekcijom u bedro, trbušnu stijenku, glutealno ili deltoidno područje.
Insulatard can be used in children and adolescents. 
Insulatard se može koristiti u djece i adolescenata.
Suspension for injection 1 vial of 10 ml. 
Suspenzija za injekciju 1 bočica od 10 ml.
Always mix Insulatard and fast-acting insulin in the same sequence. 
Uvijek miješajte Insulatard i brzodjelujući inzulin istim redoslijedom.
Combination of Insulatard with pioglitazone 
Kombinacija lijeka Insulatard s pioglitazonom
Just before use, roll the vial of Insulatard between your hands until the liquid is uniformly white and cloudy. 
Neposredno prije primjene provaljajte Insulatard bočicu između dlanova dok tekućina ne postane jednoliko bijela i zamućena.
Patients transferred to Insulatard from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products. 
Bolesnicima koji su prešli na Insulatard s druge vrste inzulina možda će biti potreban veći broj injekcija dnevno ili različita doza nego kod primjene njihovih uobičajenih inzulinskih pripravaka.
When transferring from other intermediate or long-acting insulin medicinal products, adjustment of the Insulatard dose and timing of administration may be necessary. 
Pri prijelazu s drugih srednjedugodjelujućih ili dugodjelujućih inzulinskih pripravaka možda će biti potrebno prilagoditi dozu i vrijeme primjene lijeka Insulatard.
After removing Insulatard vial, cartridge or pre-filled pen from the refrigerator, it is recommended to allow the Insulatard vial, cartridge or pre-filled pen to reach room temperature before resuspending the insulin as instructed for first time use. 
6.6 Posebne mjere za zbrinjavanje i druga rukovanja lijekom Nakon što se izvadi iz hladnjaka, preporučuje se pustiti Insulatard bočicu, uložak ili napunjenu brizgalicu da dosegne sobnu temperaturu prije resuspendiranja inzulina prema uputama za prvu uporabu.
Insulatard is presented as a suspension for injection. 
Insulatard je suspenzija za injekciju.
Inject the air into the vial containing Insulatard and pull out the needle. 
Ubrizgajte zrak u bočicu s lijekom Insulatard i izvucite iglu.
There is no restriction on treatment with Insulatard during breast-feeding. 
Nema ograničenja za liječenje lijekom Insulatard tijekom dojenja.
Push the needle into the vial of Insulatard, turn the vial and syringe upside down and draw out the dose you have been prescribed. 
Gurnite iglu u bočicu lijeka Insulatard, preokrenite bočicu i štrcaljku i navucite propisanu dozu.
Instructions on how to use Insulatard suspension for injection in InnoLet Read the instructions carefully before using your InnoLet. 
Upute za uporabu Insulatard suspenzije za injekciju u brizgalici InnoLet Prije uporabe brizgalice InnoLet pozorno pročitajte ove upute.
Instructions on how to use Insulatard suspension for injection in FlexPen Read the following instructions carefully before using your FlexPen. 
Upute za uporabu Insulatard suspenzije za injekciju u brizgalici FlexPen Prije uporabe brizgalice FlexPen pozorno pročitajte ove upute.
How to use Insulatard Dose and when to take your insulin 
Doza i kada trebate primijeniti inzulin
Insulatard contains less than 1 mmol sodium (23 mg) per dose, i.e. Insulatard is essentially ‘sodiumfree'. 
Insulatard sadrži manje od 1 mmol (23 mg) natrija po dozi tj.
How to handle Insulatard InnoLet 
Kako rukovati brizgalicom Insulatard InnoLet
On rare occasions, injection site reactions may require discontinuation of Insulatard. 
Zbog reakcija na mjestu injiciranja rijetko će biti potrebno prekinuti liječenje lijekom Insulatard.
Draw into the syringe the same amount of air as the dose of Insulatard. 
Navucite u štrcaljku količinu zraka koja je jednaka dozi lijeka Insulatard.
Insulatard is an isophane (NPH) human insulin suspension. 
Insulatard je suspenzija humanog izofan (NPH) inzulina.
You must use the pen as described in the Instructions on how to use Insulatard FlexPen. 
Brizgalicom morate rukovati na način opisan u uputama za uporabu Insulatard FlexPen brizgalice.
Insulatard FlexPen is a pre-filled disposable pen containing human insulin as isophane (NPH). 
Insulatard FlexPen je jednokratna napunjena brizgalica koja sadrži humani inzulin u obliku izofana (NPH).
Expel any air from the syringe and check that the dose is correct. 
Izbacite zrak iz štrcaljke i provjerite da li je doza točna.
You must use the pen as described in the Instructions on how to use Insulatard InnoLet. 
Brizgalicom morate rukovati na način opisan u uputama za uporabu Insulatard InnoLet brizgalice.
How to handle Insulatard FlexPen 
Kako rukovati brizgalicom Insulatard FlexPen
► After each injection, be sure to remove and discard the needle and store Insulatard without the needle attached. 
Nakon svakog injiciranja iglu obavezno skinite i bacite u otpad te spremite Insulatard bez pričvršćene igle.
► Needles and Insulatard Penfill must not be shared. 
► Igle i Insulatard Penfill ne smiju se dijeliti s drugim osobama.
► Needles and Insulatard InnoLet must not be shared. 
► Igle i Insulatard InnoLet ne smiju se dijeliti s drugim osobama.
Insulatard is administered by injection under the skin (subcutaneously). 
Insulatard je namijenjen injiciranju pod kožu (supkutano).
Insulatard vial (100 international units/ml) 
Insulatard bočica (100 internacionalnih jedinica/ml)
Insulatard vial (40 international units/ml) 
Insulatard bočica (40 internacionalnih jedinica/ml)
How to take Insulatard 
Kako čuvati Insulatard
Insulatard vial (100 international units/ml), Penfill and FlexPen: 
Insulatard bočica (100 internacionalnih jedinica/ml), Penfill i FlexPen: Novo Nordisk A/S
Before using Insulatard 
Prije primjene lijeka Insulatard
► Needles and Insulatard FlexPen must not be shared. 
► Igle i Insulatard FlexPen ne smiju se dijeliti s drugim osobama.
Read carefully the Instructions on how to use Insulatard FlexPen included in this package leaflet. 
Pažljivo pročitajte upute za uporabu Insulatard FlexPen brizgalice u ovoj Uputi o lijeku.
Read carefully the Instructions on how to use Insulatard InnoLet included in this package leaflet. 
Pažljivo pročitajte upute za uporabu Insulatard InnoLet brizgalice u ovoj Uputi o lijeku.
Insulatard Penfill/Insulatard InnoLet/Insulatard FlexPen During use or when carried as a spare: The product can be stored for a maximum of 6 weeks. 
Insulatard bočica (40 internacionalnih jedinica/ml) Tijekom uporabe ili kad se lijek nosi kao rezervni: lijek se može čuvati najviše 4 tjedna.
Insulatard InnoLet is only suitable for subcutaneous injections. 
Insulatard InnoLet je prikladan samo za potkožne injekcije.
Insulatard vials are for use with insulin syringes with a corresponding unit scale. 
Kako primijeniti Insulatard Insulatard bočice koriste se s inzulinskim štrcaljkama s odgovarajućom jediničnom skalom.
Insulatard FlexPen is only suitable for subcutaneous injections. 
Insulatard FlexPen je prikladan samo za potkožne injekcije.
Insulatard Penfill is only suitable for subcutaneous injections from a reusable pen. 
Insulatard Penfill je prikladan samo za potkožne injekcije iz brizgalice za višekratnu uporabu.
► Insulatard FlexPen is only suitable for injecting under the skin. 
► Insulatard FlexPen je prikladan samo za ubrizgavanje pod kožu.
► Insulatard Penfill is only suitable for injecting under the skin using a reusable pen. 
► Insulatard Penfill je prikladan samo za ubrizgavanje pod kožu pomoću brizgalice za višekratnu uporabu.
What Insulatard is and what it is used for What you need to know before you use Insulatard How to use Insulatard 
Što morate znati prije nego počnete primjenjivati Insulatard Kako primjenjivati Insulatard
► Insulatard InnoLet is only suitable for injecting under the skin. 
► Insulatard InnoLet je prikladan samo za ubrizgavanje pod kožu.
Insulatard is indicated for treatment of diabetes mellitus. 
4.1 Terapijske indikacije Insulatard je indiciran za liječenje šećerne bolesti.
Insulatard Penfill EU/1/02/233/005 EU/1/02/233/006 EU/1/02/233/007 
EU/1/02/233/005 EU/1/02/233/006 EU/1/02/233/007
Insulatard vial (40 international units/ml)/Insulatard vial (100 international units/ml) Administration with a syringe 
Insulatard bočica (40 internacionalnih jedinica/ml)/Insulatard bočica (100 internacionalnih jedinica/ml)
Insulatard FlexPen is only suitable for injecting under the skin. 
Insulatard FlexPen je prikladan samo za ubrizgavanje pod kožu.
Paediatric population Insulatard can be used in children and adolescents. 
Primjena u djece i adolescenata Insulatard se može primjenjivati u djece i adolescenata.
Insulatard InnoLet is only suitable for injecting under the skin. 
Insulatard InnoLet je prikladan samo za ubrizgavanje pod kožu.
METHOD AND ROUTE OF ADMINISTRATION 
NAČIN I PUTEVI PRIMJENE LIJEKA
Insulatard InnoLet EU/1/02/233/010 EU/1/02/233/011 EU/1/02/233/012 
EU/1/02/233/010 EU/1/02/233/011 EU/1/02/233/012
Insulatard Penfill is only suitable for injecting under the skin using a reusable pen. 
Insulatard Penfill je prikladan samo za ubrizgavanje pod kožu pomoću brizgalice za višekratnu uporabu.
Insulatard Penfill is designed to be used with Novo Nordisk insulin delivery systems and NovoFine or NovoTwist needles. 
Novo Nordisk i iglama NovoFine ili NovoTwist.
Insulatard InnoLet is a pre-filled disposable pen containing human insulin as isophane (NPH). 
Insulatard InnoLet je jednokratna napunjena brizgalica koja sadrži humani inzulin u obliku izofana
How to inject Insulatard 
Kako primjenjivati Insulatard
Insulatard FlexPen EU/1/02/233/013 EU/1/02/233/014 EU/1/02/233/015 
EU/1/02/233/013 EU/1/02/233/014 EU/1/02/233/015
► Inject the insulin under your skin. 
Kako injicirati Insulatard ► Injicirajte inzulin pod kožu.
Insulatard FlexPen 100 international units/ml suspension for injection in pre-filled pen. 
Insulatard FlexPen 100 internacionalnih jedinica/ml suspenzija za injekciju u napunjenoj brizgalici.
Insulatard 40 IU/ml Suspension for injection Insulin human 
Insulatard 40 IU/ml Suspenzija za injekciju humani inzulin
Insulatard FlexPen is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm. FlexPen delivers 1-60 units in increments of 1 unit. 
FlexPen je namijenjen za uporabu s jednokratnim iglama NovoFine ili NovoTwist, duljine do 8 mm.
Insulatard Penfill 100 international units/ml suspension for injection in cartridge. 
Insulatard Penfill 100 internacionalnih jedinica/ml suspenzija za injekciju u ulošku.
Insulatard 40 international units/ml suspension for injection in vial. 
Insulatard 40 internacionalnih jedinica/ml suspenzija za injekciju u bočici.
Insulatard 100 IU/ml Suspension for injection Insulin human 
Insulatard 100 IU/ml Suspenzija za injekciju humani inzulin
Resuspension of Insulatard 
Miješanje lijeka Insulatard
Insulatard InnoLet 100 international units/ml suspension for injection in pre-filled pen. 
Insulatard InnoLet 100 internacionalnih jedinica/ml suspenzija za injekciju u napunjenoj brizgalici.
Insulatard Penfill 100 IU/ml Suspension for injection Insulin human SC 
Insulatard Penfill 100 IU/ml Suspenzija za injekciju humani inzulin s.c.
Insulatard FlexPen 100 IU/ml Suspension for injection in pre-filled pen Insulin human 
Insulatard FlexPen 100 IU/ml Suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Insulatard vial (40 international units/ml)/Insulatard vial (100 international units/ml) Vial (type 1 glass) closed with a disc (bromobutyl/polyisoprene rubber) and a protective tamper-proof plastic cap containing 10 ml of suspension. 
Bočica (staklo tipa 1) zatvorena pločicom (brombutilna/poliizoprenska guma) i zaštitnim plastičnim zatvaračem s evidencijom otvaranja sadrži 10 ml suspenzije.
Insulatard 100 international units/ml suspension for injection in vial. 
Insulatard 100 internacionalnih jedinica/ml suspenzija za injekciju u bočici.
Insulatard Penfill 100 IU/ml Suspension for injection in cartridge Insulin human 
Insulatard Penfill 100 IU/ml Suspenzija za injekciju u ulošku humani inzulin
Insulatard FlexPen 100 IU/ml Suspension for injection Insulin human 
Insulatard FlexPen 100 IU/ml Suspenzija za injekciju humani inzulin s.c.
Preparing your Insulatard FlexPen 
Priprema Insulatard FlexPen brizgalice
Package leaflet: Information for the user Insulatard 40 IU/ml (international units/ml) suspension for injection in vial human insulin 
Uputa o lijeku: Informacije za korisnika Insulatard 40 IU/ml (internacionalnih jedinica/ml) suspenzija za injekciju u bočici humani inzulin
Insulatard 40 IU/ml Suspension for injection Insulin human SC 
Insulatard 40 IU/ml Suspenzija za injekciju humani inzulin s.c.
Insulatard InnoLet 100 IU/ml Suspension for injection in pre-filled pen Insulin human 
Insulatard InnoLet 100 IU/ml Suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Insulatard InnoLet is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm. InnoLet delivers 1-50 units in increments of 1 unit. 
InnoLet je namijenjen za uporabu s jednokratnim iglama NovoFine ili NovoTwist, duljine do 8 mm.
EU/1/02/233/003 1 vial of 10 ml EU/1/02/233/004 5 vials of 10 ml 
EU/1/02/233/004 5 bočica od 10 ml
Package leaflet: Information for the user Insulatard FlexPen 100 IU/ml (international units/ml) suspension for injection in pre-filled pen human insulin 
Uputa o lijeku: Informacije za korisnika Insulatard FlexPen 100 IU/ml (internacionalnih jedinica/ml) suspenzija za injekciju u napunjenoj brizgalici humani inzulin
► Insulatard Penfill cartridges are designed to be used with Novo Nordisk insulin delivery systems and NovoFine or NovoTwist needles. 
Insulatard InnoLet je napunjena brizgalica namijenjena uporabi s jednokratnim iglama NovoFine ili
Package leaflet: Information for the user Insulatard Penfill 100 IU/ml (international units/ml) suspension for injection in cartridge human insulin 
Uputa o lijeku: Informacije za korisnika Insulatard Penfill 100 IU/ml (internacionalnih jedinica/ml) suspenzija za injekciju u ulošku humani inzulin
Package leaflet: Information for the user Insulatard InnoLet 100 IU/ml (international units/ml) suspension for injection in pre-filled pen human insulin 
Uputa o lijeku: Informacije za korisnika Insulatard InnoLet 100 IU/ml (internacionalnih jedinica/ml) suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Insulatard 100 IU/ml Suspension for injection Insulin human SC 
Insulatard 100 IU/ml Suspenzija za injekciju humani inzulin s.c.
EU/1/02/233/013 1 pen of 3 ml EU/1/02/233/014 5 pens of 3 ml EU/1/02/233/015 10 pens of 3 ml 
EU/1/02/233/014 5 brizgalica od 3 ml
EU/1/02/233/001 1 vial of 10 ml EU/1/02/233/002 5 vials of 10 ml 
EU/1/02/233/002 5 bočica od 10 ml
Package leaflet: Information for the user Insulatard 100 IU/ml (international units/ml) suspension for injection in vial human insulin 
Uputa o lijeku: Informacije za korisnika Insulatard 100 IU/ml (internacionalnih jedinica/ml) suspenzija za injekciju u bočici humani inzulin
Insulatard InnoLet 100 IU/ml Suspension for injection Insulin human 
Insulatard InnoLet 100 IU/ml Suspenzija za injekciju humani inzulin s.c.
EU/1/02/233/010 1 pen of 3 ml EU/1/02/233/011 5 pens of 3 ml EU/1/02/233/012 10 pens of 3 ml 
EU/1/02/233/011 5 brizgalica od 3 ml
EU/1/02/233/016 5 packs of 1 x 10 ml vial 
EU/1/02/233/012 10 brizgalica od 3 ml
EU/1/02/233/005 1 cartridge of 3 ml EU/1/02/233/006 5 cartridges of 3 ml EU/1/02/233/007 10 cartridges of 3 ml 
EU/1/02/233/006 5 uložaka od 3 ml
9 March 2017 
9. ožujka 2017.
The European Commission issued a decision on this opinion on 9/03/2017. 
Europska komisija objavila je odluku o ovom mišljenju 9. ožujka 2017.
It is also available under other trade names: Clexane, Clexane T, Clexane Forte, Klexane, Qualiop, Enoxaparin Sanofi and Enoxaparine Sanofi. 
Dostupan je i pod drugim trgovačkim nazivima: Clexane, Clexane T, Clexane Forte, Klexane, Qualiop, Enoxaparin Sanofi i Enoxaparine Sanofi.
What is Lovenox? 
Što je Lovenox?
The regimen should be selected by the physician based on an individual assessment including evaluation of the thromboembolic risk and of the risk of bleeding. 
Režim liječenja treba odabrati liječnik na temelju individualne procjene, uključujući procjenu rizika od tromboembolije i rizika od krvarenja.
Patients at higher risk should be given 100 IU/kg (1 mg/kg) twice daily. 
Bolesnici u kojih je rizik veći trebaju primati 100 IU/kg (1 mg/kg) dva puta dnevno.
The CHMP agreed that Lovenox can be used for the following uses: 
CHMP se složio da se lijek Lovenox može upotrebljavati u sljedećim slučajevima:
• to treat certain types of myocardial infarction (heart attack); 
• za liječenje određenih vrsta infarkta miokarda (srčani udar);
The Committee also harmonised other sections of the SmPC including sections 4.4 (special warning and precautions), 4.5 (interaction with other medicinal products and other forms of interaction), 4.6 (fertility, pregnancy and lactation), 4.7 (effects on ability to drive and use of machines) and 4.8 (undesirable effects). 
Odbor je također uskladio druge dijelove u sažetku opisa svojstava lijeka, uključujući dio 4.4 (posebna upozorenja i mjere opreza), 4.5 (interakcije s drugim lijekovima i drugi oblici interakcija), 4.6 (plodnost, trudnoća i dojenje), 4.7 (utjecaj na sposobnost upravljanja vozilima i rada sa strojevima) i 4.8 (nuspojave).
A contraindication that existed in some EU member states for use in patients with severe kidney impairment was removed. 
Kontraindikacija koja je postojala u nekim državama članicama EU-a za primjenu u bolesnika s teškim oštećenjem funkcije bubrega uklonjena je.
Lovenox is available in all EU countries. 
Lovenox je dostupan u svim zemljama Europske unije.
The company that markets these medicines is Sanofi. 
Te lijekove u promet stavlja tvrtka Sanofi.
Why was Lovenox reviewed? 
Zašto je Lovenox ponovno ocjenjivan?
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that there is a need to harmonise the prescribing information for Lovenox in the European Union (EU). 
Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji zaključio je da postoji potreba za usklađivanje informacija za propisivanje lijeka Lovenox u Europskoj uniji (EU).
A table with dosing recommendations in this group was included. 
Uključena je i tablica s preporukama za doziranje u toj skupini bolesnika.
This section was also updated to reflect that outside its approved use in haemodialysis Lovenox is not recommended in patients with end stage kidney disease. 
Ovaj dio izmijenjen je i kako bi se pokazalo da se izvan svoje odobrene primjene u hemodijalizi, Lovenox ne preporučuje u završnom stadiju bolesti bubrega.
The CHMP agreed that the strength of the active substance enoxaparin will now be expressed both in international units (IU) and in milligram (mg) throughout the product information. 
CHMP se složio da će se u cijelom tekstu informacija o lijeku jačina djelatne tvari enoksaparina izražavati i u međunarodnim jedinicama (IU) i u miligramima (MG).
Lovenox contains the active substance enoxaparin. 
Lovenox sadrži djelatnu tvar enoksaparin.
• to prevent clots forming when blood is circulated through a haemodialysis machine to remove toxic substances. 
• za sprječavanje nastanka ugrušaka kada krv cirkulira kroz uređaj za hemodijalizu radi uklanjanja otrovnih tvari.
Lovenox is authorised in the EU via national procedures. 
Lovenox je u Europskoj uniji odobren nacionalnim postupcima.
It is available as vials, ampoules, prefilled syringes and pens and is given by injection under the skin or into a vein. 
Dostupan je u bočicama, ampulama, napunjenim štrcaljkama i brizgalicama, a daje se injekcijom pod kožu ili u venu.
For the treatment of deep vein thrombosis and pulmonary embolism, the CHMP also clarified that the dose regimen of 150 IU/kg (1.5 mg/kg) given once daily should only be used only in uncomplicated patients who have a low risk of a further venous thromboembolism. 
CHMP je također razjasnio da se za liječenje duboke venske tromboze i plućne embolije režim doze od 150 IU/kg (1,5 mg/kg) jednom dnevno treba primjenjivati samo u bolesnika koji su jednostavni slučajevi s malim rizikom od daljnje venske tromboembolije.
On 12 November 2015, France referred the matter to the CHMP in order to harmonise the marketing authorisations for Lovenox in the EU. 
Francuska je 12. studenoga 2015. uputila predmet CHMP-u radi usklađivanja odobrenja za stavljanje u promet lijeka Lovenox u Europskoj uniji.
Lovenox is an anticoagulant medicine (a medicine to prevent blood clots) used in adults to prevent and treat conditions associated with blood clots such as deep vein thrombosis (where the clot develops in a deep vein, usually in the leg), as well as unstable angina (a severe type of chest pain caused by problems with the blood flow to the heart) and certain types of myocardial infarction (heart attack); 
Lovenox je antikoagulacijski lijek (lijek za sprječavanje nastanka krvnih ugrušaka) koji se primjenjuje u odraslih za sprječavanje i liječenje bolesti povezanih s krvnim ugrušcima kao što je duboka venska tromboza (kada se u dubokoj veni razvije ugrušak, obično u nozi), a također i nestabilna angina (teška vrsta bola u prsima prouzročenog tegobama s dotokom krvi u srce) i nekim vrstama infarkta miokarda (srčani udar);
The CHMP, in light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets should be harmonised across the EU. 
U svjetlu dostavljenih podataka i znanstvene rasprave unutar Odbora, mišljenje je CHMP-a da se sažeci opisa svojstava lijekova, označivanje i upute za lijekove moraju uskladiti na razini EU-a.
• to prevent venous thromboembolism (blood clots that form inside the veins, obstructing blood flow), especially in patients who are having surgery or who are at greater risk of clots because they have reduced mobility due to illness; 
• za sprječavanje venske tromboembolije (krvnih ugrušaka koji nastaju unutar vena i ometaju protok krvi), posebice u bolesnika koji se podvrgavaju kirurškom zahvatu ili u kojih je rizik od stvaranja ugrušaka veći zbog smanjene pokretljivosti uzrokovane bolešću;
On 15 December 2016, the European Medicines Agency completed a review of Lovenox and associated names. 
Europska agencija za lijekove završila je ocjenjivanje lijeka Lovenox i pridruženih naziva 15. prosinca 2016.
• to treat unstable angina (a severe type of chest pain caused by problems with the blood flow to the heart); 
• za liječenje nestabilne angine pektoris (teška vrsta bola u prsima prouzročenog tegobama s dotokom krvi u srce);